AN2 Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Rhea-AI Impact

(Low)

Rhea-AI Sentiment

(Neutral)

Tags

conferences

01/29/2025 - 04:00 PM

MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO, will present at the Oppenheimer 35^th Annual Healthcare Life Sciences Conference.

Details of the event are as follows:

Oppenheimer 35^th Annual Healthcare Life Sciences Conference (virtual)

Eric Easom, Co-Founder, Chairman, President and CEO will provide a corporate overview on Wednesday, February 12, 2025 at 3:20pm ET.

A webcast of the presentation can be accessed on the Investors section of the AN2 Therapeutics website at www.an2therapeutics.com. An archived replay will be available for at least 30 days following the presentation.

About AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. AN2 has a pipeline of boron-based compounds in development for Chagas disease, NTM, and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. For more information, please visit our website at www.an2therapeutics.com.